+

WO2007009691A3 - Combination of substituted pyrazolines and anti -addictive agent - Google Patents

Combination of substituted pyrazolines and anti -addictive agent Download PDF

Info

Publication number
WO2007009691A3
WO2007009691A3 PCT/EP2006/006965 EP2006006965W WO2007009691A3 WO 2007009691 A3 WO2007009691 A3 WO 2007009691A3 EP 2006006965 W EP2006006965 W EP 2006006965W WO 2007009691 A3 WO2007009691 A3 WO 2007009691A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination
addictive agent
active substance
substance combination
substituted pyrazolines
Prior art date
Application number
PCT/EP2006/006965
Other languages
French (fr)
Other versions
WO2007009691A2 (en
Inventor
Helmut H Buschmann
Original Assignee
Esteve Labor Dr
Helmut H Buschmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05384009A external-priority patent/EP1749525A1/en
Application filed by Esteve Labor Dr, Helmut H Buschmann filed Critical Esteve Labor Dr
Publication of WO2007009691A2 publication Critical patent/WO2007009691A2/en
Publication of WO2007009691A3 publication Critical patent/WO2007009691A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to an active substance combination comprising at least one substituted pyrazoline compound and at least one anti-addictive compound, a medicament comprising said active substance combination, a pharmaceutical formulation comprising said active substance combination and the use of said active substance combination for the manufacture of a medicament.
PCT/EP2006/006965 2005-07-15 2006-07-15 Combination of substituted pyrazolines and anti -addictive agent WO2007009691A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05384009A EP1749525A1 (en) 2005-07-15 2005-07-15 Combination of substituted pyrazolines and anti-addictive agent
EP05384009.6 2005-07-15
US70548305P 2005-08-05 2005-08-05
US60/705,483 2005-08-05

Publications (2)

Publication Number Publication Date
WO2007009691A2 WO2007009691A2 (en) 2007-01-25
WO2007009691A3 true WO2007009691A3 (en) 2007-03-08

Family

ID=37492008

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/006965 WO2007009691A2 (en) 2005-07-15 2006-07-15 Combination of substituted pyrazolines and anti -addictive agent

Country Status (2)

Country Link
ES (1) ES2319074B1 (en)
WO (1) WO2007009691A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2677205A1 (en) * 2007-01-31 2008-08-07 University Of Virginia Patent Foundation Topiramate plus naltrexone for the treatment of addictive disorders
JP2011515076A (en) 2008-02-28 2011-05-19 ユニバーシティ オブ バージニア パテント ファウンデーション Serotonin transporter gene and treatment of alcoholism
EP2585049A1 (en) 2010-06-24 2013-05-01 Merz Pharma GmbH & Co. KGaA Neramexane multiple unit dosage form
SI2801625T1 (en) 2010-07-02 2018-04-30 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
AU2012221704B2 (en) 2011-02-23 2013-12-05 Coeruleus Ltd. Flumazenil complexes, compositions comprising same and uses thereof
WO2013036721A1 (en) 2011-09-09 2013-03-14 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
WO2020023792A1 (en) * 2018-07-27 2020-01-30 Amygdala Neurosciences, Inc. Combination therapy for nicotine addiction
WO2023244574A1 (en) 2022-06-14 2023-12-21 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0429360A2 (en) * 1989-11-22 1991-05-29 Laboratorios Del Dr. Esteve, S.A. Inhibition of withdrawal syndrome
WO1993012791A1 (en) * 1991-12-20 1993-07-08 Merck Sharp & Dohme Limited Central cholecystokinin antagonists having pharmaceutical activity
GB2359488A (en) * 2000-02-28 2001-08-29 Britannia Pharmaceuticals Ltd Restricting reinstatement of drug use
EP1384477A1 (en) * 2001-04-06 2004-01-28 Laboratorios Del Dr. Esteve, S.A. Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases
WO2005077911A1 (en) * 2004-02-17 2005-08-25 Laboratorios Del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0429360A2 (en) * 1989-11-22 1991-05-29 Laboratorios Del Dr. Esteve, S.A. Inhibition of withdrawal syndrome
WO1993012791A1 (en) * 1991-12-20 1993-07-08 Merck Sharp & Dohme Limited Central cholecystokinin antagonists having pharmaceutical activity
GB2359488A (en) * 2000-02-28 2001-08-29 Britannia Pharmaceuticals Ltd Restricting reinstatement of drug use
EP1384477A1 (en) * 2001-04-06 2004-01-28 Laboratorios Del Dr. Esteve, S.A. Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases
WO2005077911A1 (en) * 2004-02-17 2005-08-25 Laboratorios Del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments

Also Published As

Publication number Publication date
WO2007009691A2 (en) 2007-01-25
ES2319074B1 (en) 2009-12-03
ES2319074A1 (en) 2009-05-01

Similar Documents

Publication Publication Date Title
AP2405A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms.
WO2007002597A3 (en) Modified-release formulations of a bupropion salt
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
WO2007014124A3 (en) High drug load formulations and dosage forms
WO2006124047A3 (en) Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
WO2007090661A3 (en) Active substance combination comprising azolylcarbinol compounds
WO2007022255A3 (en) Pharmaceutical formulations for sustained release
WO2007009721A3 (en) Indoline-substituted pyrazoline derivatives, their preparation and use as medicaments
TR200604349A2 (en) Pharmaceutical compositions containing aripiprazole
WO2009061431A3 (en) Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
WO2008003050A3 (en) Gallium nitrate formulations
WO2007095039A3 (en) Pharmaceutical formulations
WO2007009701A3 (en) Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
WO2007087026A3 (en) Solid-state form of amg 706 and pharmaceutical compositions thereof
WO2009120389A8 (en) Oral and injectable formulations of tetracycline compounds
EP1584335A3 (en) Active substance combination comprising a carbinol composition and an opioid
WO2005117895A3 (en) Compositions comprising meloxicam
WO2007011958A3 (en) Intraoral dosage forms of glucagon
WO2007009686A3 (en) Substituted pyrazoline compounds, their preparation and use as medicaments
MXPA06011467A (en) Active substance combination comprising a carbinol combined to at least an nsaid.
EA201101119A1 (en) DOSABLE FORM CONTAINING PANTOPRAZOL AS AN ACTIVE INGREDIENT
WO2008004100A3 (en) Therapeutic compounds
WO2007121471A3 (en) Dialkyl ether delivery agents
WO2007005763A3 (en) Combination of a renin inhibitor and an insulin secretion enhancer or an insulin sensitizer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 200750087

Country of ref document: ES

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P200750087

Country of ref document: ES

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06776263

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 200750087

Country of ref document: ES

Kind code of ref document: A

WWG Wipo information: grant in national office

Ref document number: 200750087

Country of ref document: ES

Kind code of ref document: A

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载